Second exit this year

Almada Ventures Sells TailorMed for About $7.6 Million

The publicly traded R&D partnership will record a gross cash profit of about $5 million in a deal reflecting a 3.15x multiple on its investment • Control of the company will pass to U.S. private equity firm GrowthCurve Capital

Publicly traded R&D partnership Almada Ventures reported today (Monday) another full exit. Portfolio company TailorMed, which operates in digital health, completed a merger transaction under which New York-based private equity firm GrowthCurve Capital became its controlling shareholder.

Manor Zemer, CEO of Almada Ventures. Courtesy photo.jpg
Manor Zemer, CEO of Almada | Photo: PR

As part of the move, Almada is selling its entire stake in the company for gross cash proceeds of about $7.6 million.

A 3.15x multiple on the investment

Immediately before the transaction was completed, Almada held about 3.05% of TailorMed's share capital on a fully diluted basis. Against a cumulative investment cost of about $2.42 million, the current proceeds reflect a multiple of about 3.15x on the money and are expected to generate a gross profit of about $5 million for the partnership before taxes and expenses.

Signing a deal. Photo: Shutterstock
Signing a deal | Photo: Shutterstock

The value of the stake on the partnership's books stood at just about $3.97 million at the end of June 2026, meaning the proceeds achieved in the transaction are significantly higher than the book value.

Record year for exits and cash distributions

The current transaction caps a series of successful exits for Almada during 2026.

Earlier this year, the partnership completed the sale of BioProtect to medical device giant Olympus in a $270 million transaction that generated a profit of about $8 million for Almada, alongside a profitable partial exit from Clanz Technologies.

The U.S. dollar
The U.S. dollar | Photo: Shutterstock

This series of exits enabled Almada to reach $12 million in approved distributions to investors over the course of the year, including capital reductions and dividends, placing the partnership in the top decile for cash returns relative to 2020-vintage funds, according to benchmark data from Carta.

Accelerating artificial intelligence technologies in medicine

TailorMed develops technology solutions for health care providers, pharmacies and patients, aimed at easing the financial burden associated with medical treatments.

Medicine and artificial intelligence, illustration
Medicine and artificial intelligence, illustration | Photo: raker, Shutterstock

GrowthCurve Capital's entry as controlling shareholder is intended to accelerate the expansion of TailorMed's operations and support the continued development of artificial intelligence-based solutions for the U.S. and global health care markets.

Key takeaways

  • Almada Ventures is selling its entire stake in TailorMed for about $7.6 million in gross cash proceeds.
  • The transaction implies a multiple of about 3.15x on Almada's cumulative investment cost of about $2.42 million and is expected to generate about $5 million in gross profit before taxes and expenses.
  • Before the deal closed, Almada held about 3.05% of TailorMed's share capital on a fully diluted basis.
  • The value of Almada's stake on its books at the end of June 2026 was about $3.97 million, below the transaction proceeds.
  • The sale follows other 2026 exits, including BioProtect and a partial exit from Clanz Technologies, and helped Almada reach $12 million in approved investor distributions this year.

Questions and answers

How much is Almada Ventures getting for its TailorMed stake?
Almada is selling its entire stake for gross cash proceeds of about $7.6 million. The company says this should produce a gross profit of about $5 million before taxes and expenses.
Who will control TailorMed after the deal?
Control of TailorMed will pass to GrowthCurve Capital, a New York-based private equity firm. The transaction is described as a merger deal that made GrowthCurve Capital the controlling shareholder.
What does TailorMed do?
TailorMed develops technology solutions for health care providers, pharmacies and patients. Its products are aimed at easing the financial burden associated with medical treatments.

Share this story

About the writer

Shai Nogai

Writes for TV10, Israel’s economic channel. This story was translated from the original Hebrew.

More stories by Shai Nogai

More for you